Skip to Main Content

Paper Details

Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
Clin Cancer Res
0
2023
Glioblastoma, Patients, Recurrent, Recurrent glioblastoma, VEGF, bevacizumab, cabozantinib, irinotecan, patients, recurrent glioblastoma, tumor
Author NameAffiliation
Benjamin M Ellingsonuniversity of california los angeles Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M Ellingsonuniversity of california los angeles Neuro-Oncology Program, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonUniversity of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M Ellingsonuniversity of california los angeles Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonUniversity of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M Ellingsonuniversity of california los angeles Neuro-Oncology Program, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Josep Garcia
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School
Timothy F Cloughesyuniversity of california los angeles Neuro-Oncology Program, University of California Los Angeles
Timothy F CloughesyDavid Geffen School of Medicine, University of California Los Angeles
Timothy F Cloughesyuniversity of california los angeles Neuro-Oncology Program, University of California Los Angeles
Timothy F CloughesyDavid Geffen School of Medicine, University of California Los Angeles
  • 1 - 20

Datasets